PMC:7160614 / 6579-7484 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"143","span":{"begin":168,"end":176},"obj":"Species"},{"id":"144","span":{"begin":282,"end":290},"obj":"Species"},{"id":"145","span":{"begin":313,"end":321},"obj":"Species"},{"id":"146","span":{"begin":335,"end":341},"obj":"Species"},{"id":"147","span":{"begin":360,"end":368},"obj":"Species"},{"id":"148","span":{"begin":557,"end":565},"obj":"Species"},{"id":"149","span":{"begin":628,"end":636},"obj":"Species"},{"id":"150","span":{"begin":273,"end":281},"obj":"Disease"},{"id":"151","span":{"begin":619,"end":627},"obj":"Disease"}],"attributes":[{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Tax:9606"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Tax:9606"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:9606"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Tax:9606"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:9606"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"Tax:9606"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"Tax:9606"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"MESH:C000657245"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T43","span":{"begin":273,"end":281},"obj":"Disease"},{"id":"T44","span":{"begin":619,"end":627},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T36","span":{"begin":153,"end":154},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":259,"end":260},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"0_colil","denotations":[{"id":"32300971-29948074-67436","span":{"begin":31,"end":33},"obj":"29948074"},{"id":"32300971-30093881-67436","span":{"begin":31,"end":33},"obj":"30093881"},{"id":"32300971-30546304-67436","span":{"begin":31,"end":33},"obj":"30546304"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"TEST0","denotations":[{"id":"32300971-31-37-67436","span":{"begin":31,"end":33},"obj":"[\"29948074\", \"30093881\", \"30546304\"]"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"2_test","denotations":[{"id":"32300971-29948074-29373584","span":{"begin":31,"end":33},"obj":"29948074"},{"id":"32300971-30093881-29373584","span":{"begin":31,"end":33},"obj":"30093881"},{"id":"32300971-30546304-29373584","span":{"begin":31,"end":33},"obj":"30546304"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"LitCovid-sentences","denotations":[{"id":"T55","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"T56","span":{"begin":138,"end":258},"obj":"Sentence"},{"id":"T57","span":{"begin":259,"end":540},"obj":"Sentence"},{"id":"T58","span":{"begin":541,"end":714},"obj":"Sentence"},{"id":"T59","span":{"begin":715,"end":905},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}

{"project":"MyTest","denotations":[{"id":"32300971-29948074-29373584","span":{"begin":31,"end":33},"obj":"29948074"},{"id":"32300971-30093881-29373584","span":{"begin":31,"end":33},"obj":"30093881"},{"id":"32300971-30546304-29373584","span":{"begin":31,"end":33},"obj":"30546304"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"According to previous studies [19–21], whose sample size is comparable with ours, the ratio between primary and validation cohort is 7:3. In this study, a total of 136 patients were divided into primary (n = 98) and validation (n = 38) cohorts, close to 7:3. A total of 19 COVID-19 patients from two hospitals (6 patients from Meizhou People’s Hospital and 13 patients from the First Affiliated Hospital of Shantou University Medical College) and 19 randomly selected controls from Meizhou City were incorporated into the validation cohort. The rest of the patients are incorporated in the primary cohort, including 51 COVID-19 patients from Huizhou, Yongzhou, and Shantou cities and 47 controls from Meizhou City. The primary cohort was utilized to select the most valuable features and build the predictive model, and the validation cohort was used to evaluate and validate the performance of the model."}